Compare APPN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APPN | NVAX |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2017 | 1996 |
| Metric | APPN | NVAX |
|---|---|---|
| Price | $23.19 | $8.46 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 9 |
| Target Price | ★ $33.83 | $11.33 |
| AVG Volume (30 Days) | 633.3K | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 101.59 | ★ 309.76 |
| EPS | 0.02 | ★ 2.58 |
| Revenue | $226,743,000.00 | ★ $1,123,479,000.00 |
| Revenue This Year | $13.79 | N/A |
| Revenue Next Year | $10.56 | N/A |
| P/E Ratio | $1,199.50 | ★ $3.47 |
| Revenue Growth | 28.29 | ★ 64.69 |
| 52 Week Low | $21.77 | $5.01 |
| 52 Week High | $46.06 | $11.85 |
| Indicator | APPN | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.36 | 38.12 |
| Support Level | $21.77 | $8.01 |
| Resistance Level | $31.10 | $9.05 |
| Average True Range (ATR) | 0.95 | 0.54 |
| MACD | -0.16 | -0.23 |
| Stochastic Oscillator | 4.89 | 1.81 |
Appian Corp is a low-code enterprise platform-as-a-service company focusing on business process management. The company's Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. The company also provides maintenance and support as well as consulting services and training related to its platform. The majority of its revenue is subscription-based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform. Geographically, the company derives maximum revenue from its business in the United States.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.